3.3000 0.00 (0.00%)
After hours: 5:59PM EST
|Bid||3.2900 x 3000|
|Ask||3.3500 x 1300|
|Day's range||2.9100 - 3.3000|
|52-week range||0.8800 - 9.0200|
|Beta (5Y monthly)||3.05|
|PE ratio (TTM)||N/A|
|Earnings date||06 May 2021 - 11 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||6.71|
Ladies and gentlemen, thank you for standing by, and welcome to the Arbutus Biopharma Corporation fourth-quarter and year-end 2020 financial results and corporate update conference call. Good morning, and thank you for joining the Arbutus Biopharma fourth-quarter 2020 conference call and webcast. On the call today are Bill Collier, president and chief executive officer; Dr. Gaston Picchio, chief development officer; Dr. Michael Sofia, chief scientific officer; and Dave Hastings, chief financial officer.
Arbutus (ABUS) delivered earnings and revenue surprises of -9.52% and 12.49%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Biopharma (ABUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.